Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization Sort descending
Nov
21
2019
Nuvo Pharms. v. Dr. Reddy’s Labs. – Catch 22 at the Federal Circuit? Schwegman, Lundberg & Woessner, P.A.
Apr
27
2020
Patent Strategies For Expedited Chinese Approval Of Medical Devices Schwegman, Lundberg & Woessner, P.A.
Aug
21
2017
Athena Diagnostics, Inc. v. Mayo (D. Mass., August 4, 2017) – “That’s all,” She Wrote. Schwegman, Lundberg & Woessner, P.A.
Aug
1
2011
AMC v. Myriad – “Laws of Nature” Exception Does Not Include Isolated DNA Schwegman, Lundberg & Woessner, P.A.
Jan
10
2018
Aptalis Fails to “Surround’ Apotex’s Generic ER Tablet Schwegman, Lundberg & Woessner, P.A.
Nov
2
2013
Novozymes Looses “Possession” Of Its Enzyme Re: Patent Litigation Schwegman, Lundberg & Woessner, P.A.
Oct
21
2014
Biotechnology Industry Organization (BIO) Provides Supplemental Comments on PTO s.101 Guidelines Schwegman, Lundberg & Woessner, P.A.
Apr
28
2015
“Isolated” Natural Products Still in Purgatory Post-PTO Guidance? Schwegman, Lundberg & Woessner, P.A.
Nov
26
2020
Consumer Public Interest Lawsuit Seeks 21 Million RMB for Counterfeit Trademark Sales of Starbucks in China Schwegman, Lundberg & Woessner, P.A.
Apr
5
2011
Federal Court Hears Myriad Gene Case This Morning Schwegman, Lundberg & Woessner, P.A.
Aug
3
2011
Wegner Paper Probes Myriad Decisions Flaws Schwegman, Lundberg & Woessner, P.A.
May
12
2012
In re Montgomery – “Unbounded” Inherency in Patent Law Schwegman, Lundberg & Woessner, P.A.
Oct
7
2014
“The Good Wife” Defends Genetically Modified Organisms (GMOs) Schwegman, Lundberg & Woessner, P.A.
Jan
21
2015
Claim Construction in Patents: Teva v. Sandoz: “Just the facts, Ma’am” Schwegman, Lundberg & Woessner, P.A.
Jun
18
2019
Cutting Through the Patent Thicket – The Little Bill that Couldn’t Schwegman, Lundberg & Woessner, P.A.
Oct
23
2015
Australian Patent Office Proposes “Coding Only” Sequence Ban Schwegman, Lundberg & Woessner, P.A.
Sep
8
2020
XY, LLC v. Trans Ova Genetics, Inc. – Building on Illumina v. Ariosa Schwegman, Lundberg & Woessner, P.A.
Jul
6
2021
China Releases Patent Linkage Implementation Measures Schwegman, Lundberg & Woessner, P.A.
Mar
1
2012
Last Chapter In The “Corn Wars” Or Just The Latest? Schwegman, Lundberg & Woessner, P.A.
Oct
8
2012
Supreme Court to Review Monsanto v. Bowman Schwegman, Lundberg & Woessner, P.A.
Nov
11
2013
Ariosa Diagnostics v. Sequenom: Another One Bites The Dust Schwegman, Lundberg & Woessner, P.A.
Feb
21
2014
Federal Circuit Reaffirms Cybor Standard in Lightning Ballast Rehearing Schwegman, Lundberg & Woessner, P.A.
Mar
9
2015
Novartis Wins Landmark Biosimilar Approval Schwegman, Lundberg & Woessner, P.A.
Feb
6
2020
Method of Treatment Efficacy Benchmarks Avoid Inherency Attack Schwegman, Lundberg & Woessner, P.A.
Mar
28
2016
Superman Breyer v. Batman Lourie Battle in Sequenom Petition for Cert. Schwegman, Lundberg & Woessner, P.A.
Jan
21
2015
Teva v. Sandoz pt.II– The Dissent And The Zone Of Uncertainty Schwegman, Lundberg & Woessner, P.A.
Mar
19
2015
Enzo Biochem V. Applera Corp. – When “Words Can Hurt You” Schwegman, Lundberg & Woessner, P.A.
Mar
22
2016
Sequenom Files Petition for Cert. After Invalidation of Cff Patent Schwegman, Lundberg & Woessner, P.A.
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins